Skip to main content

pelacarsen

pelacarsen: 7 clinical trials tracked.

pelacarsen evidence translation

What we can confirm

7 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about pelacarsen, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 1 study sponsors
Clinical Trials (7)

Managed Access Programs for TQJ230, Pelacarsen

NCT07000695·NVS
Available
Expanded AccessNovartis Pharmaceuticals

A Randomized, Double-blind, Placebo-controlled, Multicenter Study Evaluating the Efficacy, Safety, Tolerability, and Coronary Plaque Effects of Early Pelacarsen (TQJ230) Initiation in Patients in the US With Elevated Lp(a) and Recent Acute Coronary Syndrome

NCT07625306·Phase 3·NVS
Not yet recruiting

Primary endpoint: Change in log-transformed Lp(a) concentration

InterventionalRandomizeddouble240 targetStarted 2026-08Completion 2028-12Novartis Pharmaceuticals

A Single Arm, Multicenter, Open-label Extension (OLE) Trial to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230) in Participants Who Completed the Parent Lp(a)HORIZON Trial

NCT07517263·Phase 3·NVS
Recruiting

Primary endpoint: Number of participants with Adverse events

Interventionalopen5,700 targetStarted 2026-05Completion 2030-0150 sites · United StatesNovartis Pharmaceuticals

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD

NCT06875973·Phase 3·NVS
Recruiting

Primary endpoint: Incidence of Adverse events (AEs) or serious adverse events (SAEs)

Interventionalopen599 targetStarted 2025-05Completion 2030-1250 sites · United StatesNovartis Pharmaceuticals

A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Atherosclerotic Cardiovascular Disease (ASCVD), and Elevated LDL-C and Lp(a)

NCT06813911·Phase 3·NVS
Recruiting

Primary endpoint: Change in log transformed lipoprotein A (Lp(a)) concentration

InterventionalRandomizeddouble340 targetStarted 2025-04Completion 2028-0250 sites · China, France, United StatesNovartis Pharmaceuticals

A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis [Lp(a)FRONTIERS CAVS]

NCT05646381·Phase 2·NVS
Recruiting

Primary endpoint: Change in peak aortic jet velocity

InterventionalRandomizeddouble502 targetStarted 2024-03Completion 2030-0350 sites · Austria, Belgium, Canada, United StatesNovartis Pharmaceuticals

A Randomized, Double-blind, Placebo-controlled, Multicenter Trial Assessing the Reduction of the Rate of Lipoprotein Apheresis After Treatment With Pelacarsen (TQJ230) Compared to Placebo in Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease Undergoing Weekly Lipoprotein Apheresis in Germany

NCT05305664·Phase 3·NVS
Completed

Primary endpoint: Rate of Lipoprotein Apheresis Sessions Performed Over 52 Weeks Normalized to the Weekly Lipoprotein Apheresis Schedule

InterventionalRandomizedquadruple51 enrolledStarted 2022-08Completion 2025-0113 sites · GermanyNovartis Pharmaceuticals